Nunzia Pharmaceutical Company
Nunzia Pharmaceutical Company (NUNZ) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nunz · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Nunzia Pharmaceutical CompanyYou NUNZ | $0M | N/A | — | -$0.26 |
 ARYx Therapeutics, Inc. ARYX | $0M | N/A | — | -$1.21 |
 Abattis Bioceuticals Corp. ATTBF | $0M | N/A | — | -$0.01 |
 Instadose Pharma Corp. INSD | $0M | N/A | — | -$0.01 |
 Isodiol International Inc. ISOLF | $0M | N/A | — | -$2.35 |
 Nutranomics, Inc. NNRX | $1M | N/A | — | -$0.00 |
 Onassis Holdings Corp. ONSS | $0M | N/A | — | -$0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Nunzia Pharmaceutical Company (NUNZ) measures how much investors pay for each dollar of the company's trailing earnings. NUNZ's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.26.
Frequently asked questions
NUNZ pe ratio · 6 questionsNUNZ's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of -$0.26. Data sourced from Financial Modeling Prep via NUNZ's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Nunzia Pharmaceutical Company SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09